| SELLAS LIFE SCIENCES GRP |
| USA |
| Gesundheit |
| US81642T2096 / A2PU3T |
| RXK3 (Frankfurt) / SLS (NASDAQ) |
| FRA:RXK3, ETR:RXK3, RXK3:GR, NASDAQ:SLS |
| - |
| https://www.sellaslifesci.. |
|
Sellas Life Sciences Group Inc. is a biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapies. Its chief aim is to address unmet medical needs in onco..
>Volltext.. |
| 594.41 Mio. EUR |
| 557.12 Mio. EUR |
| - |
| -22.8 Mio. EUR |
| -21.96 Mio. EUR |
| -0.24 EUR |
| 0.51 Mio. EUR |
| 37.6 Mio. EUR |
| -25.92 Mio. EUR |
| 7.5 |
| - |
| 23.75% |
| - |
| - |
| - |
| - |
| SELLAS LIFE |
| 02.03.26 |
|
||||
|
||||
|
||||
|
||||
|